EL.En. S.p.A. (ELN) Earnings Call Transcript & Summary
March 16, 2021
Earnings Call Speaker Segments
Bianca Fersini-Mastelloni
unknown<<foreign_lang>> Nicola, please proceed.
Nicola Fiore
unknownAll right. Good afternoon, everyone, and welcome to the conference call on El.En.'s 2020 Financial Results. This call is being recorded. So there will be a chance to ask questions at the end of the call. Joining me are Andrea Cangioli, El.En.'s Managing Director, and Enrico Romagnoli, El.En.'s Chief Financial Officer and Investor Relator. Before we start, please be aware that management will make a remark on this conference call regarding future expectations, plans and prospects as well as forward-looking statements. Some statements on this call — including those that address the company's beliefs, plans, objectives, estimates or expectations of possible future results or events — are forward-looking statements. Forward-looking statements carry known or unknown risks, including general economic and business conditions, along with conditions in the industry in which the company operates, and they may be affected if the assumption proves inaccurate. As a result, no forward-looking statement can be guaranteed, and actual future results, performance or achievements could differ materially from those expressed or implied by such forward-looking statements. The company assumes no obligation regarding content, nor to update the forward-looking statement to reflect events or circumstances that may arise after the date hereof. But at this point, I want to turn the call over to Andrea Cangioli.
Nicola Fiore
unknownPlease proceed, Andrea.
Andrea Cangioli
executiveThank you, Nicola, for that introduction. And thank you as well, Bianca, for the introduction. Good afternoon, everyone, and welcome to this earnings call, which we are holding following the release of the 2020 financials and the guidance for fiscal year 2021. As is customary, Enrico Romagnoli is with me on this call. In a few minutes, he will walk us through the financial details following my brief introduction. Once again, we are extremely pleased with how our group performed in the most challenging environment we have ever confronted, overcoming the restrictions and limitations that continue to weigh heavily on our businesses and our lifestyle. We were able to achieve an increase in sales volume and generate profit, which we did an excellent job of under the circumstances. Our Q4 performance was outstanding, surpassing our own forecast, and the concern about the impact of the restrictions that were put in place in early November in Italy, Germany, France, among others, and demonstrating that despite the general economic problems that are evident and plain for everyone to see, our activities are back on the path of solid growth in revenues and income that we had planned for the group. The pandemic hit us hard and forced us to depart from that path.
Andrea Cangioli
executiveIt caused us to move more slowly and put a cloud over how we performed. On the very same earnings call 1 year ago, I was giving an update on the Chinese lockdowns that had made us shut down our plant in Wuhan, Wenzhou and Lin Yi. A few days after that, Italy was to adopt the Chinese approach, and in Italy and France we had to close or sharply scale back all of our operations. If I compare how this Q4 turned out against the internal quarterly budgets we put together in late 2019, I see that we match them and even exceed them in some segments. And last, when I consider the momentum our different business units currently have in terms of orders intake, the picture looks very close to the position we aimed for and planned to be in today when we set our plans before the pandemic, back in 2019. I'd like to say a few words about what made such a strong comeback possible, because we are, naturally, pleased with our latest results, yet our pride in them goes beyond pleasure, given the foundations on which those results rest and have been built.
Andrea Cangioli
executiveWhat stands out most clearly is the vision we have shown in planning our logistics and production infrastructure. Anyone who has been with us over recent years is familiar with the scale of the investments we have made to grow our production capacity—in the medical and industrial areas alike, though most heavily in the laser cutting business in Italy and in China. And naturally, when I look at Q4 2020, where the number of systems delivered in China was twice what it was in Q4 2019, I recognize—we all recognize—that this would not have been achievable without the bold strides taken earlier. Yet the single most important factor lies in the overall capabilities of our organization—capabilities resting on a very solid foundation built from human resources of inestimable quality. Our people not only carry with them layers of knowledge, know-how, and expertise that let them and us master all the science and technology required to develop new innovative devices effectively, but the harsh trial of the pandemic also revealed the resilience and deep commitment our people devote to the company. The company did its part by establishing all the safety precautions and procedures that enabled employees to work safely and, most importantly, to feel safe in the workplace.
Andrea Cangioli
executiveWhen it comes to how effective the deliverables were, the response was outstanding. Not one development milestone was missed—even in those months when we had to make extensive use of payroll protection programs, which cut the hours available to the company and reduced income for employees. I think it matters, both for me as Managing Director and for all of you as shareholders, to understand how solid this base of our business is. And at a time when the mantra of sustainability runs through our vision and the way we approach business, you should know that the human resources leg of our long-term business sustainability infrastructure is very, very strong. The stronger traction in revenue growth is coming through the laser cutting business. We are active in that business in Italy with Cutlite Penta, based nearby here in Prato, and with our Chinese Penta Laser company, based in Wuhan, Wenzhou and Lin Yi. What is driving the sustained growth of this segment is technological innovation and the application breakthroughs that follow. The laser power available for laser cutting systems rose exponentially over this last year. A couple of years ago, we were thrilled to be able to use a 10-kilowatt laser source.
Andrea Cangioli
executiveRight now, we're putting in laser systems that come with 30-kilowatt laser sources. Meanwhile, the price of those laser sources has kept falling, which has done a lot to boost cost effectiveness along with both technical and economic productivity. Because of that, we're seeing new application markets open up that have become within reach thanks to greater laser power. Think, for instance, of heavy-duty work in construction and the manufacturing of large technical vehicles. On top of that, we're benefiting from expansion in the application markets we already serve, thanks to the better performance and affordability of the systems we're offering today. And we're benefiting from this favorable phase because of our strong ability to integrate high-power lasers into our systems and because of the infrastructure and distribution footprint built through the investments I mentioned earlier. The direction of medical laser system sales is also encouraging. In Q4 2020, we didn't hit the same volumes we did in Q4 2019. But Q4 2019 was a record quarter. Even so, we saw strong sequential growth across every segment. Aesthetic was up in Q4, driven by the new hurls of products, which are also the backbone of our current order bookings.
Andrea Cangioli
executiveThat's also supported by product sales in Japan that we distribute locally. As I noted earlier, the large sales volumes booked for these devices—which carry a relatively thin gross margin—are among the principal factors driving the gross margin decline reflected in our 2020 financials. Urology and surgery continue to face difficulties. Hospital systems remain focused on COVID. And the new hospitalization models aren't helping, because resuming our growth will require the situation to normalize. On the urology side, we performed very strongly in consumables. Sales of the single-use and multi-use optical fibers employed in every procedure were -- we recorded an increase over 2019. Key new products launched during the second half of 2020 include the new hair removal device from Deka named Again; the new chrome device from Quanta System, a Q-Switched platform for dermatology; and a new lineup of body contouring devices featuring the introduction of muscle stimulation via high-intensity magnetic fields plus enhancements to the existing devices built on microwaves, Onda, or superluminescent laser matrixes. In urology, Fiber Dust, the new fiber-technology-based system, is now being launched, filling a range gap that our competitors sought to exploit against us.
Andrea Cangioli
executiveAnd last, for some products—Monna Lisa Touch or the new acne device, Accure Acne—we don't have exciting sales results. The good news is that our strong performance came without any material contribution from those items, and the work aimed at launching or relaunching these devices will eventually let them contribute materially, which isn't yet factored into our annual guidance. Before Enrico takes you through the financial details, please consider one general point: in Q4 2020, we incurred a onetime nonmonetary expense of EUR 2.1 million from our shares allocation to the managers of the Chinese entities. Net of this expense, consolidated EBIT margin for the quarter would have been 10%, and EBITDA margin 12.2%, beating Q4 2019 in these metrics, too. That's it for the introduction. Enrico, go ahead with the financial data comments.
Enrico Romagnoli
executiveThank you, Andrea. And as he usually does, I'll share a few specifics about our most recent financials. Because of the record turnover in Q4, turnover for 2020 came to EUR 408 million, which is 1.8% above the prior year's result and thus closes the gap that had opened during the first half of the year. Gross margin was EUR 141.6 million, a decline of 9.2% versus last year. The weight of gross margin on turnover fell from 38.9% in 2019 to 34.7% as of December 2020. That decline comes from margin compression caused by the crisis in both the medical and industrial sector, though in different ways. In the industrial sector, we also pursued the aim of growing market shares by opting to surrender some margin points, particularly once competitive pressure in China intensified after the pandemic. In the medical sector, the product mix sold saw a smaller contribution from higher-margin segments such as surgery and physiotherapy; in aesthetics, meanwhile, turnover stayed at the 2020 level, helped also by a significant rise in sales of certain products, but with lower marginality.
Enrico Romagnoli
executiveOperating costs came in at EUR 34 million, lower than the EUR 43 million recorded in 2019. The effect on turnover fell from 11% to 8.4%. Those savings came mostly from S&M expenses, thanks to limits placed on travel and to every fair and congress event being called off. Staff costs for 2020 totaled EUR 66.7 million, level with the prior year. Yet, as Andrea already noted, a onetime cost of EUR 2.1 million was booked by Penta Laser Wenzhou. Leaving that aside, the drop in labor cost stems chiefly from the government payroll protection program, like the Cassa Integrazione in Italy, which was used in France and Germany too, mostly during the first 6 months of the year. At December, the group employed more than 1,600 people, and the new hires were concentrated in China, where the factories ran at full capacity with volume beating last year's volume. EBITDA reached EUR 40.8 million, a decline of 11.9% from the EUR 46.3 million posted last year, with an impact on sales of 10% versus 11.6% a year earlier. Amortization and other accruals rose by EUR 2.6 million, reflecting the significant investment made in 2019 and in 2020 as well as the higher provision for bad debt, and this captures in the most balanced way the possible deterioration of certain credit positions.
Enrico Romagnoli
executiveThat rise breaks down into EUR 1.6 million for bad debt and risk accrual, plus EUR 1 million for higher depreciation and amortization. For 2020, the combined fixed cost — meaning operating cost, naturally, and depreciation — came down 2%, while the sales impact reached 27%, against 29% the prior year. Consequently, because the debt effect shrank, profitability — the drop in profitability at gross margin level — the 4% decline we saw was trimmed to 2% at EBIT level. And we recorded a positive balance of EUR 30.1 million, lower than the EUR 38.2 million, with a sales impact of 7.4% versus 9.5%, improving — yet improving profitability during the second half in line with our latest guidance. The pretax result came to EUR 27.9 million, hit by a negative ForEx effect and a negative contribution from associated companies. Net income reached EUR 20.2 million, with a tax rate of 19% against 26% a year earlier. During 2020, certain onetime benefits arose, including remission of the IRAP balance 2019 along with the first down payment 2020; IRAP is an Italian income tax levied on the accounting of deferred tax assets for some assets revaluated under Italian law.
Enrico Romagnoli
executiveThose benefits came to roughly EUR 3 million in total. We posted a record turnover of EUR 140 million in the fourth quarter. And it's worth noting that the same explanation we gave for the full year also accounts for the drop in gross margin and profitability in Q4. Meanwhile, profitability recovered, with an EBIT margin of 8.6%, which was below Q4 2019 but was the best result achieved in 2020 and higher in total value than last year's Q4 operating result. The negative ForEx impact brought income before tax down to EUR 11 million, level with Q4 2019. On net financial position, we had a positive balance of EUR 69.2 million against EUR 61.4 million last year. And roughly EUR 20 million, plus EUR 5 million as a possible earn-out, went into acquiring an important minority stake in Penta Laser Wenzhou. Investment in technical fixed assets was around EUR 30 million, down on 2019. Cash generation in the quarter was strong at EUR 19 million, thanks to the good level of activity and a reduction in net working capital compared with the first 9 months of the year.
Enrico Romagnoli
executiveTurning to how revenue splits across our businesses, you'll notice that in the medical segment — which is in 2020 — roughly 56% of the group's turnover is accounted for. COVID weighed on the sales trend, which posted a decline of around 5%, a bit steeper on system sales than on aftersales services and consumables, and those benefited, among other things, from rising revenues in optical fibers for urological surgery. The Aesthetic segment's resilience is extraordinary, posting slight growth versus 2019. Two main reasons sit behind this result. The first is the market launch of a new system for hair removal, as Andrea already mentioned, and for body and skin treatments, with a high degree of innovation that has found great success. The second is the strong performance of our Japanese branch, with upgrades on the installed base and seats of interesting volume of locally produced equipment through the same channels. Conversely, sales in surgery — and even more markedly in physiotherapy — were hit by the COVID pandemic, since the attention of medical health structures focused mainly on treating COVID problems. In the industrial segment, a sales increase of 23% is the increase of the cutting.
Enrico Romagnoli
executiveThe 13% gain in industrial was a brilliant result considering the circumstances. In Q4, that increase reached 52%, driven by the excellent performance of the cutting segment. The cutting segment was up 23% in 2020, thanks to the 2 last excellent quarters, with growth of 75% in Q4 and 43% in Q3. The other 3 main segments — marking, source and after-sale service — kept suffering from the pandemic's effect and posted a double-digit decrease, with no meaningful improvement during the quarter. Turning to how revenue is distributed across geographical areas, the countries contributing most strongly to growth are those outside Europe. In the medical sector, we did very well in Japan, where COVID had a less incisive impact and where our own branch set a record turnover of EUR 45 million for the year, plus 60% over 2019. And in the U.S. market, where our distributors in the medical sector performed well despite a very adverse environmental condition for most of the year. The drops recorded in Italy and in Europe should be considered excellent results in light of the extended lockdown periods and various restrictions suffered. In the industrial sector, in China, the activity of the cutting sector maintained a record space in the second half of the year, and Cutlite Penta too showed a brilliant performance on Italian and European markets.
Enrico Romagnoli
executiveFor the full year 2020, the Chinese company posted revenue of EUR 107 million—up 21% year-on-year and up 106% in Q4. Cutlite Penta also had a very strong year, with turnover of EUR 50 million, up 60% year-on-year, and 20% in Q4. Andrea, please go ahead.
Andrea Cangioli
executiveAll right, thank you. Thanks, Enrico. To wrap up the presentation, we'll finish with the 2021 guidance, and I'd like to say a few words about the images shown here. Normally the before and after is a static effect. In this case, the before and after relates to the fresco in the Casa dei Ceii in Pompei, where we had to remove some of the deposits, and I think it has genuinely come back to life. In any case, we're enjoying a period of positive momentum overall, despite the ongoing uncertainty that the pandemic casts over the economic environment, and the difficulties we keep running into in certain of our business segments. Our business positioning looks very promising as this 2021 begins, and we confirm that we look forward to carrying on with our aggressive growth plan. On this slide, for 2021 we target revenue growth above 10%, which will bring an increase in EBIT, and we hope for, and will work hard toward, an increase in EBIT margin. Thank you for your attention. I think we can now proceed to the Q&A session.
Bianca Fersini-Mastelloni
unknown<<operator_script>>
François Robillard
analystThis is François Robillard calling in from Intermonte. Am I coming through clearly?
Andrea Cangioli
executiveYes.
François Robillard
analystLet me start with your guidance. Could you break down the makeup of that target of more than 10% sales growth with more detail, giving it by segment? And if you can, what are your expectations for each business unit? And lastly, regarding visibility over the short term versus the long term, how much of it do you expect to be achieved in the first half versus the second half, for example? Then my second question concerns gross margin. Can you give us an indication of your gross margin for the industrial and medical activities for the full year? And within your new guidance, what margins do you anticipate — can we expect some sort of return to the levels of the previous year, particularly in the industrial segment? And my last question is about fixed costs. Which of the savings seen in 2020 do you expect to remain structural in 2021?
Andrea Cangioli
executiveThanks a lot, François. Regarding the mix, I mean, you also have to take into account what sort of year we're comparing against right now. So the comparison is with 2020, which — I mean, in absolute terms it was a fairly weak year. We're pleased with what we managed to deliver, but it was weak, particularly for medical. At this point, our development plans remain bullish for the industrial business. And although industrial grew in 2020, we think it will outgrow the makeup business in 2021. That's also because of the sales mix we had in 2020, which we expect to be rebalanced, with a smaller contribution from the sole distribution component, based on what we can see today. And we — I mean, the model calls for 10%, let's say, with sharper growth in industrial. So as far as the long-term and short-term view is concerned, and where the gain will come from? Naturally, after Q1, there will be a huge gain in industrial, since Q1 is the quarter when we had close to 0 revenue in China. And right now, China, as I said during my introduction, is running at full speed.
Andrea Cangioli
executiveAll 4 of our factories are currently operating at essentially maximum capacity. There's still a bit of headroom available. However, our strategy calls for needing our fifth plant, located in Lin Yi, to come online sometime this year so we can keep expanding and keep producing the higher volumes that are being requested of us. For the first quarter, the year-over-year comparison will be more difficult on the medical side, since Q1 of 2020 was quite strong in medical because the shortage in demand occurred just after that first quarter wrapped up. Naturally, we expect a very substantial revenue increase across the first 2 quarters, and we anticipate that this revenue growth relative to 2020 will gradually shrink as we get to Q3 and Q4 of 2020, which were two solid quarters — the fourth quarter in particular was excellent. On gross margin, which connects to profitability and also connects to the careful guidance we've given on profitability: we're extremely happy with what we're achieving on gross margins in the industrial segment. We held those gross margins steady even as volume rose.
Andrea Cangioli
executiveThat produced a strong leverage effect for us, and it showed clearly in the bottom line. On the medical business, we're taking a cautious stance, because over the course of 2020 the share of our sales going to the U.S. rose within our group. So we felt very good about what we accomplished with our key distributors in the United States — Cynosure and Cartessa — across many aesthetic applications, international medical lasers for surgical use, and additional inputs for urology. But one thing we have to keep in mind is that the weak U.S. dollar has already hurt our marginality on medical system sales as the year ended. And for 2021 we model gross margin using a foreign exchange rate of 1.21, which naturally matters given that the bulk of our costs sit in euro, even though some of our costs are in U.S. dollars regardless. So we buy things that partly offset the foreign exchange losses we incur on sales — I mean, the effect of the dollar's weakness doesn't constrain our capacity to improve gross margin. If the dollar were to strengthen again into the 1.1 area, or even better the 1.05 to 1.06 range where it sat through 2019 and the first months of 2020, our marginality would improve materially.
Andrea Cangioli
executiveWhen it comes to fixed costs, the model we're using assumes a slow return, so we're modeling a modest rise in fixed costs. From this standpoint, 2020 has been, let's say, amazing, thanks to the savings we saw on travel and congresses. Meals and lodging, I mean, have been extremely, extremely material. In a sense, we hope those savings disappear, since that would signal a return to normality. On the other hand, we know it's going to take a long time, and unfortunately I'm not sure 2021 will be enough for life to go back to how it was before. I also believe business travel will take a while to become normal again the way it was at the end of 2019. So from this standpoint we aren't planning to hold expenses at that same very low level, but we are modeling some increase in expense without reaching the levels we had 1 year ago. I believe that covers all your questions.
François Robillard
analystYes, a quick follow-up question. You brought up the EUR 2.2 million effect from the Chinese managers selling shares — did that happen in the fourth quarter?
Andrea Cangioli
executiveYes.
Enrico Romagnoli
executiveYes.
Andrea Cangioli
executiveSo this is a share capital increase at a low price.
Bianca Fersini-Mastelloni
unknownAny questions?
François Robillard
analystSince no one else seems to have anything, I may have a few additional ones. I'm not sure whether you can hear me clearly once more. So yes, regarding the new product launches that you've announced, could you revisit that topic? And what portion of those new products will factor into your guidance? Then on working capital — in 2020, it came back down to 18% of sales. Should we anticipate a return to a more pre-COVID level above 20% as early as 2021?
Andrea Cangioli
executiveOn the new products side, yes — a number of them will feed into sales growth. Our confidence is particularly high when it comes to the new hair removal offerings. These are, again, the laser system distributed through the Deka network, plus the hair removal solution system — sorry, the hair removal system — that we supply on our own basis to Cynosure, our long-standing partner, and that will be a significant component of sales growth in 2021. On top of that, we hold strong expectations for the body shaping devices. At present we offer a very broad portfolio of body shaping devices. Keep in mind that we had been absent from the minimally invasive, or noninvasive, body shaping device market. Our entry came with Onda Coolwaves back in 2018. Following that, additional systems have arrived in this segment — Onda Coolwaves in particular. We had the superluminescent matrix products known as B-Star and Physiq, and after a study period those are now being launched in the United States. So our hopes are high for a very good year with these products in the United States. As for Europe, we introduced the systems that deliver muscle stimulation via high-intensity magnetic fields. Those new technologies are extremely compelling, both in terms of their capacity to generate revenue and because their profitability was fairly interesting.
Andrea Cangioli
executiveSo they’re one of the key pillars supporting our growth, in terms of both revenue and market presence. On the industrial side of the business, the new offerings involve launching very high-power laser systems. During Q1 2021, we installed our first 30-kilowatt system. And since progress never stops, I believe that within the next month we’ll begin working with 40-kilowatt laser systems. What I mean is that this whole push toward higher powers lets us, as I said earlier, move into new market segments and new markets, and the R&D work on supplying higher-power laser sources is likewise delivering cheaper laser sources from the same manufacturers, and it lets us bring costs down while keeping margins more or less unchanged, and therefore to expand the markets. As for net working capital, we’re very pleased with what we managed to accomplish in 2020. It’s rather strange to say, but in the areas where we didn’t have problems, where the market held its size or at least stayed vital, our customers came back paying us better than they did previously. And then the other part stems from how we manage inventory.
Andrea Cangioli
executiveNaturally, managing inventory resulted in a quite significant working-capital expansion once demand, which had dropped suddenly in the first quarter and the second quarter, came back. What I've observed since, over these recent months, is that we once more had to build up our inventories — and I think that's something we'll have to do going forward to an even greater degree, since we're running into certain supply-chain difficulties. Some components are critical. They may not cost much, yet they are essential to producing our systems. I mean certain electronics, chips and/or other electronic parts whose lead times shifted all at once — moving from a typical lead time of between 8 and 10 weeks to as much as 24 or 30 weeks at times. You can see that when you must plan a production-volume increase based on an anticipated sales increase, so that customers don't wait for months, you have to purchase ahead of time — carrying a financial burden, because you must buy early and likely pay early, and there's risk as well, since naturally there's the market risk that the sales volume you planned doesn't actually materialize.
Andrea Cangioli
executiveSadly, we have no alternative for handling this, since right now — as I said — our order books are very solid. We're having a hard time at our production facilities to deliver on time in line with what customers are executing. But if we began delivering over a longer horizon, customers would just come back rather than switch to a competitor. So we definitely must provide a certain service level on delivery to customers, and we're already prepared to put more investment into working capital so as not to lose that opportunity. And it won't be simple, because at least as has always been the case following stretches of severe economic slump, the entire supply chain is — I mean, it's not — I wouldn't call it entirely disrupted, but there are certain areas where delivery times grow far longer, since production facilities aren't ready for a sudden rebound in demand.
Andrew Dodford
analystIf I could squeeze in one quick question. Andrew Dalford, Metzger Research. Well, to start, congratulations on those results, especially given what was surely a very difficult 2020. Could you update us on what you expect for CapEx in 2021? And beyond that, are there any major investments you have in the works for the years ahead?
Andrea Cangioli
executiveYes. CapEx is going to be pretty much in line with 2020, I believe. We've already kicked off 2021 with the biggest investment we have planned for the year, the Cutlite Penta plant — that's the industrialized cutting manufacturing facility located here in Prato, close to Florence. We bought another building so as to expand its production footprint; that was absolutely necessary and it was planned. In fact, we had already disclosed the transaction back in 2020. For accounting purposes, though, it took effect at the beginning of 2021. It's a EUR 5 million investment in fixed assets. Then, over the course of the year, we'll finish our second building in Lin Yi. Lin Yi is the last of the factories we started, and the last of our ventures, so to speak, that we launched in the Shandong region. Shandong sits between Beijing and Shanghai and is a heavily industrialized region. So having a production facility in that area made sense. That will be an investment of roughly EUR 2.5 million, EUR 3 million — over EUR 2.5 million, over EUR 3 million, coming on stream in 2021. On top of that, there are other investments, because as you know, over the last year we've been putting a lot of money into all the infrastructure.
Andrea Cangioli
executiveOur business is highly dynamic, and we also have to remodel and refurbish the older infrastructure. For example, this year we're planning a fairly large investment in a building located across the road here in Calenzano. That building was mainly used as a deposit. During 2021, we plan to refurbish it, to take down the roof and put up a new one with solar panels. What I mean is it will be a green building, a sustainable building, and it will give us more surface for our operations, which are slowly increasing. So on the bottom line, CapEx should be more or less at the same order of magnitude as 2020. We aren't planning any other large investments in terms, let's say, of M&A or of internal restructuring. We did quite a lot in 2020. I remember we gained a larger share of our joint venture in China by purchasing most of the minority shares from our initial financial partner. As of today, we own about 85% of Penta Laser Wenzhou, which is the headquarter of the whole Chinese activities. And today, also owning Cutlite Penta in Italy. So we have a unique unit controlling the whole laser cutting business.
Andrea Cangioli
executiveHowever, we aren't planning — or at minimum, as of today we have no plan — to make any other big financial investments in 2021.
Trevor Fitzgerald
analystAndrea, are you able to hear me?
Andrea Cangioli
executiveYes.
Trevor Fitzgerald
analystTrevor Fitzgerald here, from Mirabaud Asset Management. I’m curious about the authorization to repurchase shares. Could you walk us through the rationale behind the buyback, how large it is, and how you’re balancing dividends against returning cash to shareholders through this route?
Andrea Cangioli
executiveTrevor, buying back stock isn’t a major issue. We’ve always kept that option available for whatever situations arise. So we also have — some agreements with particular managers that require us to give them shares. That means we need a reserve for repurchasing shares so we’re able to hand shares to those managers instead of paying them in cash; we have arrangements of that kind. And for another reason at this point, there isn’t any genuine pressing necessity, as we’ve acted in the past, and the last occasion we did so was, I think, 2 years ago. We’re keeping that tool available, if and when circumstances require us to use it.
Bianca Fersini-Mastelloni
unknownIs there anything else anyone would like to ask?
Andrea Bonfà
analystAndrea Bonfa here, from Banca Akros. If I can, I'd like to put a few questions to you. Is that all right, Bianca?
Andrea Cangioli
executiveSure.
Bianca Fersini-Mastelloni
unknownYes, absolutely. Of course.
Andrea Bonfà
analystOkay, Andrea, a few quick things from me. First, I'd like to understand whether the mix between medical and aesthetical will get better, since Japan would — as you put it — involve more sales of your own products rather than third-party ones. That's my first question. Second, the shares that were granted to the Chinese manager — is there something there that could be repeated in '21 as well, or is that just a one-off item? Third, going from memory here, your tax rate for 2020 was quite low. Is that sustainable or not? And on new products, if you could just remind us briefly, as you mentioned earlier, which new products are you going to launch this year that weren't present last year — I mean 2020 — or that didn't contribute?
Andrea Cangioli
executiveAndrea, I missed the first part of what you asked. What was it — were you asking about medical sales?
Andrea Bonfà
analystYes, so — right. If I've got this right, sales in Japan this year have been really strong, and that's thanks to your distribution of third-party products. So this year, the mix in Japan will lean more toward El.En. products rather than third-party ones. So if, say, the mix for medical aesthetical improves as a result, that's ultimately what it comes down to.
Enrico Romagnoli
executiveExactly. Yes, the answer is yes. Our current model is that although this type of sale boosted sales volume in 2020, we are modeling a decline in that kind of sale in 2021. But because we're modeling faster growth in sales of all the other systems, we would see very interesting growth in medical sales in 2021. And for the mixed balance reason, we'll also see a margin increase. The only issue with margins in the medical system, where we have a better mix — we'll have a better mix, and we have new products with very higher margins — is that a large part of our sales is directed to the U.S. And in the U.S., we have contracts in U.S. dollars on which we cannot change the prices, or at least it is not appropriate for us to change the prices. So margin R&D will suffer a little bit from the weak dollar. The new products we are counting on for 2020 — 2021, excuse me, that have not been great contributors in 2020 are the body shaping system that I was mentioning before that we're starting to sell in big volumes at the beginning of 2021.
Enrico Romagnoli
executiveTurning to the hair removal devices — the new ones I brought up earlier — again, and Elite, which only went into standard production and decent-volume production at the end of the year, so their impact on our financials came in Q4 alone, while we expect them to contribute steadily and materially across all of 2021. I can't recall whether there was another question...
Andrea Bonfà
analystRegarding the tax rate, there's a question — I can put it to you if you'd like.
Andrea Cangioli
executiveYeah, yeah — on the tax rate, I was about to, so Enrico, go ahead and take the tax rate question.
Enrico Romagnoli
executiveRight, right. The 2020 tax rate did include a onetime benefit, which I mentioned in the presentation. So that won't recur. The 2020 tax rate is 19%, versus 26% last year. So for projecting the tax rate going forward, you could say somewhere from 25% to 28%, roughly.
Andrea Bonfà
analystAnd regarding the shares going to the Chinese managers — is that a one-time thing? Or were you — was that something...
Andrea Cangioli
executiveRight, so actually that plan consists of 2 parts. Still, my sense is the first batch here is roughly 3 or 4x bigger than the second one. So a second bench will come, and I wouldn't call it negligible, though it's significantly smaller. My hope is that against higher revenue and profits, it will end up negligible.
Andrea Bonfà
analystAll right. And if I could squeeze in one final question, would you be able to give us a rough reminder of what your U.S. sales came to for 2020?
Andrea Cangioli
executiveYeah, yeah — a bit under $50 million.
Andrea Bonfà
analystFor Europe — is that in euros, or is it USD 50 million?
Andrea Cangioli
executiveIn dollars.
Bianca Fersini-Mastelloni
unknownAre there any further questions? If nothing else comes up, we'll bring this conference to a close. Andrea?
Andrea Cangioli
executiveThat’s great. Thanks for joining us. I think I’ll be seeing most of you at the STAR conference next week. And with some of you, I know we’ll also be talking before long. In any case, thanks for spending time with us, and have a good evening. Goodbye.
Enrico Romagnoli
executiveTake care.
Bianca Fersini-Mastelloni
unknownAppreciate you joining the call. Goodbye.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete EL.En. S.p.A. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to EL.En. S.p.A. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in EL.En. S.p.A. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.